This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Ewan Cameron | |
|---|---|
| Name | Ewan Cameron |
| Birth date | 6 February 1922 |
| Birth place | Glasgow |
| Death date | 11 September 1991 |
| Death place | Dunoon |
| Occupation | Physician, Cancer researcher |
| Known for | Research on ascorbic acid in cancer treatment |
| Nationality | United Kingdom |
Ewan Cameron was a Scottish physician and clinical researcher known for advocating high-dose ascorbic acid (vitamin C) in the treatment of malignancy and for clinical collaborations with Linus Pauling. His work connected clinical observation at the Vale of Leven Hospital with biochemical hypotheses about oxidative stress, collagen, and wound healing in cancer. Cameron became a polarizing figure, attracting attention from proponents such as Linus Pauling and criticism from mainstream institutions including National Cancer Institute investigators.
Born in Glasgow in 1922, Cameron was educated at local schools before attending medical training at the University of Glasgow. During his formative years he encountered medical figures and institutions associated with Scottish clinical practice, including exposure to contemporaries from Royal Infirmary of Edinburgh and clinical traditions linked to Royal College of Physicians of London and British Medical Association debates. After qualifying in medicine he undertook house appointments and later posts that connected him to hospitals in Scotland, developing an interest in surgical and medical aspects of oncology care within district hospital systems.
Cameron served as a consultant physician at the Vale of Leven Hospital in Dumbartonshire, where he managed patients with malignant neoplasm and coordinated palliative and postoperative care. His clinical responsibilities brought him into contact with multidisciplinary teams from institutions such as Guy's Hospital, Royal Marsden Hospital, and academic centres like the University of Glasgow Medical School. Cameron participated in clinical meetings involving surgeons from St Thomas' Hospital and oncologists associated with Royal College of Radiologists, and he contributed case series that informed debates at meetings of the British Oncological Association and regional health boards.
Cameron became notable for conducting clinical investigations into the use of high-dose ascorbic acid for patients with advanced carcinoma. He published case series and observational reports proposing that prolonged administration of intravenous and oral ascorbate could improve subjective well-being and potentially extend survival in some patients with adenocarcinoma, sarcoma, and other tumor types. Cameron's work drew the attention of Linus Pauling, leading to collaborative trials and joint advocacy; their partnership linked Cameron's clinical experience at Vale of Leven with Pauling's biochemical and advocacy profile at California Institute of Technology and later Oregon State University. The collaboration produced clinical reports that contrasted with randomized trial results from the Mayo Clinic and prompted review by the National Institutes of Health and the National Cancer Institute in the United States.
Cameron's mechanistic proposals invoked interactions between ascorbate and physiological processes described by investigators at institutions such as Harvard Medical School, Massachusetts Institute of Technology, and Johns Hopkins Hospital. He suggested that ascorbate might influence collagen synthesis and extracellular matrix integrity, modulate inflammation, and affect biochemical pathways of tumor progression studied by researchers at Stanford University and Cold Spring Harbor Laboratory.
Cameron's publications included case series, clinical reviews, and collaborative papers with Pauling that were disseminated in outlets read by clinicians and advocates associated with Lancet readership and critics connected to New England Journal of Medicine commentary. He advanced theories linking vitamin C deficiency, impaired wound healing and altered connective tissue to facilitation of tumor invasion and metastasis, drawing on biochemical literature from Max Planck Institute and cellular studies originating in laboratories at University of Cambridge and University of Oxford. Cameron argued for combined intravenous and oral regimens and for earlier initiation of therapy than in palliation-only frameworks espoused by some practitioners at Memorial Sloan Kettering Cancer Center and other tertiary cancer centres.
Cameron's claims provoked substantial debate. Supporters included patient advocacy groups and researchers aligned with Linus Pauling, while critics comprised investigators from Mayo Clinic, the National Cancer Institute, and editors at leading journals. Randomized, controlled trials conducted by the Mayo Clinic failed to reproduce Cameron's reported survival benefits, leading to critiques articulated in forums involving Institute of Medicine discussions and reviews by committees of the Royal Society of Medicine. Methodological concerns cited by critics included selection bias, lack of randomization, and confounding by concurrent therapies. Debates extended into public policy arenas involving United States Congress hearings on complementary therapies and regulatory discussions with agencies such as the Food and Drug Administration.
Despite criticism, Cameron's work contributed to broader examination of micronutrients in cancer care, prompting subsequent research by teams at University of Kansas Medical Center, University of Iowa, and biotechnology groups exploring pharmacologic ascorbate delivered at high plasma concentrations. His clinical observations continue to be cited in reviews addressing oxidative therapies, adjunctive oncology approaches, and historical analyses by scholars at Wellcome Trust and university history departments.
Cameron lived in Dunoon and maintained clinical commitments in the West of Scotland health system while corresponding with international collaborators. He died in 1991, leaving a contested legacy that intersects clinical observation, biochemical hypothesis, and public debate. His advocacy for vitamin C inspired subsequent laboratory research into pro-oxidant effects of pharmacologic ascorbate at institutions like Georgia Institute of Technology and renewed interest among integrative oncology groups at University of California, San Francisco. Histories of 20th-century oncology and biographies of figures such as Linus Pauling and commentators at the National Cancer Institute continue to reference Cameron's role in shaping conversations about nonconventional therapies in modern medical practice.
Category:Scottish physicians Category:1922 births Category:1991 deaths